These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30511323)

  • 21. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
    Mayer LD; Tardi P; Louie AC
    Int J Nanomedicine; 2019; 14():3819-3830. PubMed ID: 31213803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
    Maakaron JE; Mims AS
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
    Zeidner JF; Lee DJ; Frattini M; Fine GD; Costas J; Kolibaba K; Anthony SP; Bearss D; Smith BD
    Clin Cancer Res; 2021 Jan; 27(1):60-69. PubMed ID: 32998965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
    Zeidner JF; Foster MC; Blackford AL; Litzow MR; Morris LE; Strickland SA; Lancet JE; Bose P; Levy MY; Tibes R; Gojo I; Gocke CD; Rosner GL; Little RF; Wright JJ; Doyle LA; Smith BD; Karp JE
    Haematologica; 2015 Sep; 100(9):1172-9. PubMed ID: 26022709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
    van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
    Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.
    Wang H; Mao L; Yang M; Qian P; Lu H; Tong H; Xie W; Zhou D; Huang X; Wang Y; Xu G; Lu Y; Wei J; Mai W; Ye X; Meng H; Shen Y; Huang J; Yu W; Sun J; Sheng J; Yan X; Jin J; Zhu HH
    Lancet Haematol; 2022 Jun; 9(6):e415-e424. PubMed ID: 35512726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia.
    Wang J; Yang YG; Zhou M; Xu JY; Zhang QG; Zhou RF; Chen B; Ouyang J
    PLoS One; 2013; 8(4):e60699. PubMed ID: 23593285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
    Cortes JE; Douglas Smith B; Wang ES; Merchant A; Oehler VG; Arellano M; DeAngelo DJ; Pollyea DA; Sekeres MA; Robak T; Ma WW; Zeremski M; Naveed Shaik M; Douglas Laird A; O'Connell A; Chan G; Schroeder MA
    Am J Hematol; 2018 Nov; 93(11):1301-1310. PubMed ID: 30074259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
    Lin TL; Rizzieri DA; Ryan DH; Schiller GJ; Kolitz JE; Uy GL; Hogge DE; Solomon SR; Wieduwilt MJ; Ryan RJ; Faderl S; Cortes JE; Lancet JE
    Blood Adv; 2021 Mar; 5(6):1719-1728. PubMed ID: 33724305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults.
    Phillips GL; Reece DE; Shepherd JD; Barnett MJ; Brown RA; Frei-Lahr DA; Klingemann HG; Bolwell BJ; Spinelli JJ; Herzig RH
    Blood; 1991 Apr; 77(7):1429-35. PubMed ID: 2009367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
    Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
    Wiernik PH; Banks PL; Case DC; Arlin ZA; Periman PO; Todd MB; Ritch PS; Enck RE; Weitberg AB
    Blood; 1992 Jan; 79(2):313-9. PubMed ID: 1730080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
    Kaspers GJ; Zimmermann M; Reinhardt D; Gibson BE; Tamminga RY; Aleinikova O; Armendariz H; Dworzak M; Ha SY; Hasle H; Hovi L; Maschan A; Bertrand Y; Leverger GG; Razzouk BI; Rizzari C; Smisek P; Smith O; Stark B; Creutzig U
    J Clin Oncol; 2013 Feb; 31(5):599-607. PubMed ID: 23319696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
    Krug U; Röllig C; Koschmieder A; Heinecke A; Sauerland MC; Schaich M; Thiede C; Kramer M; Braess J; Spiekermann K; Haferlach T; Haferlach C; Koschmieder S; Rohde C; Serve H; Wörmann B; Hiddemann W; Ehninger G; Berdel WE; Büchner T; Müller-Tidow C; ;
    Lancet; 2010 Dec; 376(9757):2000-8. PubMed ID: 21131036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
    Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
    Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
    Talati C; Lancet JE
    Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
    Lee JH; Kim H; Joo YD; Lee WS; Bae SH; Zang DY; Kwon J; Kim MK; Lee J; Lee GW; Lee JH; Choi Y; Kim DY; Hur EH; Lim SN; Lee SM; Ryoo HM; Kim HJ; Hyun MS; Lee KH;
    J Clin Oncol; 2017 Aug; 35(24):2754-2763. PubMed ID: 28632487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.